RESUMO
Tuberculosis (TB) remains one of the leading infectious killers in the world. New anti-TB drugs and more effective drug combinations are urgently needed, particularly given the increasing incidence of drug-resistant TB and HIV-TB co-infection. This review describes the available mouse models of TB and describes their utility in the evaluation of new TB drug candidates and in the evaluation of the efficacy of new TB drug combinations. Some of the most recent patents on promising TB drug-candidates are also mentioned here.
Assuntos
Antituberculosos/farmacologia , Avaliação Pré-Clínica de Medicamentos , Tuberculose/tratamento farmacológico , Animais , Antituberculosos/química , Modelos Animais de Doenças , Farmacorresistência Bacteriana , Quimioterapia Combinada , Camundongos , Estrutura Molecular , Patentes como Assunto , Relação Estrutura-Atividade , Fatores de TempoRESUMO
The last 10 years have seen resurgent industry activity in discovery and development of new drugs for the treatment of tuberculosis (TB), a growing widespread and devastating (more than 2 million deaths annually) bacterial infection that is of increasing concern in developing and developed nations alike. This review describes drugs currently being evaluated in the clinic for treatment of uncomplicated and drug resistant pulmonary TB, and updates the literature on 5 new drugs that entered clinical trials in the last 4 years.
